Europese Unie - Nederlands - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (als fosfaat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastische middelen - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi is geïndiceerd voor de behandeling van volwassen patiënten met polycythaemia vera die resistent of intolerant is voor hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Europese Unie - Nederlands - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - andere dermatologische preparaten - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Europese Unie - Nederlands - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastische middelen - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Europese Unie - Nederlands - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastische middelen - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

janssen-cilag b.v. graaf engelbertlaan 75 4837 ds breda - itraconazol - concentraat voor oplossing voor infusie - hydroxypropylbetadex ; natriumchloride ; natriumhydroxide (e 524) ; propyleenglycol (e 1520) 3,9 mg/ml ; stikstof (head space) (e 941) ; water voor injectie ; zoutzuur (e 507), - itraconazole

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kela pharma - fenytoïnenatrium - tablet - 100 mg - fenytoïnenatrium 100 mg - phenytoin

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - itraconazol 100 mg - capsule, hard - 100 mg - itraconazol 100 mg - itraconazole

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires serb - primidon 250 mg - tablet - 250 mg - primidon 250 mg - primidone

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kela pharma sa-nv - fenytoïnenatrium 100 mg - tablet - phenytoin

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

medcor pharmaceuticals b.v. artemisweg 232 8239 de lelystad - itraconazol - drank - caramel (e 150) ; hydroxypropylbetadex ; kersensmaakstof ; natriumhydroxide (e 524) ; propyleenglycol (e 1520) 103,6 mg/ml ; saccharoide natrium x-water (e 954) ; sorbitol, vloeibaar, niet-kristalliseerbaar (e 420) ; water, gezuiverd ; zoutzuur (e 507), - itraconazole